Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

NCT07166419 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Recurrent Acute Lymphoblastic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
Recurrent Indolent Non-Hodgkin Lymphoma
Recurrent Lymphoblastic Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Acute Lymphoblastic Leukemia
Refractory Chronic Lymphocytic Leukemia
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
Refractory Indolent Non-Hodgkin Lymphoma
Refractory Lymphoblastic Lymphoma
Refractory Non-Hodgkin Lymphoma
Refractory Transformed Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL: Autologous Anti-CD19/CD20/CD22 CAR T-cells
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
DRUG: Cyclophosphamide
PROCEDURE: Echocardiography Test
DRUG: Fludarabine
PROCEDURE: Multigated Acquisition Scan
PROCEDURE: Pheresis
PROCEDURE: Positron Emission Tomography

Sponsor

Ohio State University Comprehensive Cancer Center